Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis

By LabMedica International staff writers
Posted on 11 Sep 2025

Ovarian cancer is considered one of the deadliest cancers, in part because it rarely shows clear symptoms in its early stages, and diagnosis is often complex. More...

Current approaches make it difficult to accurately triage women with ovarian cancer compared to benign conditions, and often require painful, invasive procedures such as tissue biopsies. Researchers have now developed a new nanoparticle-based approach that can highlight ovarian cancer markers more accurately than current diagnostic tools.

A project led by The University of Queensland (Brisbane, Australia) and collaborators has led to the development of a technology that uses sponge-like mesoporous gold nanoparticles to improve cancer diagnostics through their unique biosensing properties. These structures act as light amplifiers, revealing even the faintest traces of cancer markers in patient samples such as urine, saliva, or blood.

Researchers boosted the sensitivity of gold-enhanced light sensors using Surface-Enhanced Raman Scattering (SERS). Compared with commercially available nanoparticles, mesoporous gold increased sensitivity significantly, enabling tiny "hotspots" of light to amplify biomarker signals. Embedded into a diagnostic process with a small tube and handheld Raman spectrophotometer, the method has already outperformed current blood tests, achieving 82% sensitivity in confirming ovarian cancer and 98% specificity in ruling it out. The research was published in the nanoscience and nanotechnology journal Small.

The portability, affordability, and simplicity of this sensor technology make it especially promising for women in remote or under-resourced regions. By transforming disease monitoring, mesoporous nanotechnologies could reduce unnecessary procedures and help pave the way for more personalized treatment strategies. With further development, devices like this could move closer to everyday clinical use, improving survival rates through earlier and more accurate detection.

“This project demonstrates how mesoporous nanotechnologies can help us transform disease monitoring and pave the way for personalized treatment strategies,” said Javeria Bashir, nanomaterials researcher at The University of Queensland and lead developer of the technology. “Devices like this are moving closer and closer to everyday use.”

Related Links:
The University of Queensland


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.